Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?-Reference-Cited by-同舟云学术

Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

Published:2019-01 Issue: Volume:76 Page:65-69
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Di Veroli Ambra,Campagna Alessia,De Muro Marianna,Maurillo Luca,Trawinska Malgorzata Monika,LeonettiCrescenzi Sabrina,Petriccione Luca,Romano Atelda,D’Addosio Ada,Cenfra Antonia,Montanaro Marco,Felici Stefano,Andriani Alessandro,Carmosino Ida,Niscola Pasquale^ORCID,Montefusco Enrico,Breccia Massimo,Latagliata Roberto

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference21 articles.

1. Ironoverload in thalassemia: different organs at different rates;Taher;Hematology,2017

2. Iron overload in myelodysplastic syndromes;Gattermann;Int. J. Hematol.,2018

3. Iron-chelating therapy for transfusion iron overload;Brittenham;N. Engl. J. Med.,2011

4. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study;Gattermann;Leuk. Res.,2010

5. Deferasirox for transfusion-dependentpatients with myelodysplasticsyndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial);Angelucci;Eur. J. Hematol.,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases;Frontiers in Oncology;2023-02-23

2. Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis;Diseases;2022-10-09

3. Advances in Evaluation of Antioxidant and Toxicological Properties of Stryphnodendron rotundifolium Mart. in Drosophila melanogaster Model;Foods;2022-07-27

4. Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes;Blood Advances;2022-06-13

5. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study;British Journal of Haematology;2022-02-08